Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial tests the safety and side effects of zanubrutinib in combination with odronextamab and how well it works in treating patients with Richter's transformation. Zanubrutinib, a tyrosine kinase inhibitor, blocks a protein called Bruton tyrosine kinase (BTK), which may help keep cancer cells from growing. Odronextamab is a bispecific monoclonal antibody that can bind to two different antigens at the same time. Odronextamab binds to CD20 found on B-cells (a type of white blood cell) and on many B-cell cancers and to CD3 on T-cells (also a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Giving zanubrutinib in combination with odronextamab may be safe, tolerable and/or effective in treating patients with Richter's transformation.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony diagnozą transformacja Richtera (zmiana białaczki w nowotwór limfatyczny)
- •Potwierdzenie CD20 dodatniości w badaniach
- •Pacjenci niezleczeni wcześniej lub z nawrotem/opornością na leczenie
- •Widoczne powiększenie węzłów chłonnych (co najmniej 1,5 cm) lub powiększenie śledziony
- •Liczba neutrofili (pewne białe krwinki) powyżej wymaganych poziomów
- •Liczba płytek krwi powyżej wymaganych poziomów
- •Pełne wyzdrowienie z wcześniejszych działań niepożądanych leczenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
City of Hope Medical Center
Duarte, United States
Trial contact
Alexey V. Danilov
Alexey V. Danilov
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.